Last reviewed 2026-04-20 · How we verify

BNT162b2 (Omi KP.2) (bnt162b2-omi-kp-2)

BNT162b2 (Omi KP.2) is a marketed COVID-19 vaccine developed by Pfizer Inc. It prevents COVID-19 in individuals 5 years of age and older, and in those with certain health conditions. The vaccine has generated $36.8B in revenue. Its mechanism is not explicitly stated. BNT162b2 has undergone 1 clinical trial and has 0 publications. It is a key player in the COVID-19 vaccine market.

At a glance

Approved indications

• Prevention of COVID-19 in individuals 5 years of age and older
• Prevention of COVID-19 in individuals 6 months through 4 years of age
• Prevention of COVID-19 in individuals 12 years of age and older
• Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions
• Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions
• Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Corticosteroids
• Immunosuppressants
• Live vaccines
• Interferons
• Thalidomide
• SARS-CoV-2 monoclonal antibodies
• Tofacitinib
• Ruxolitinib
• Omalizumab
• Belimumab
• Vedolizumab

Key clinical trials

• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BNT162b2 (Omi KP.2) CI brief — competitive landscape report
• BNT162b2 (Omi KP.2) updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI